Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) Director Suzanne Ildstad sold 21,753 shares of the company’s stock in a transaction dated Wednesday, April 19th. The stock was sold at an average price of $2.16, for a total value of $46,986.48. Following the completion of the transaction, the director now directly owns 2,883,389 shares of the […]
Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) shares fell 0.9% on Monday . The stock traded as low as $1.08 and last traded at $1.10. 2,842 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 131,842 shares. The stock had previously closed at $1.11. Wall Street Analysts Forecast […]